Samsung Biologics Co.,Ltd.
207940
Kedudukan dalam Saham
#496
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon,... Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
Harga Saham
$1,028.49
Modal Pasaran
$47.88B
Perubahan (1 hari)
-3.67%
Perubahan (1 tahun)
-18.37%
Negara
KR
Perdagangan Samsung Biologics Co.,Ltd. (207940)
Kategori
Healthcare
Hasil untuk Samsung Biologics Co.,Ltd. (207940)
Hasil pada Sep 2026 TTM: $3.30B
Menurut laporan kewangan terkini daripada Samsung Biologics Co.,Ltd., hasil semasa syarikat (TTM) ialah $3.30B. Pada tahun 2024, syarikat memperoleh hasil sebanyak $2.38B penurunan berbanding hasil pada tahun 2023 iaitu $2.85B. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Samsung Biologics Co.,Ltd. dari 2014 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $3.30B | 4.55% |
| 2025 | $3.15B | 32.61% |
| 2024 | $2.38B | -16.65% |
| 2023 | $2.85B | 20.00% |
| 2022 | $2.38B | 80.33% |
| 2021 | $1.32B | 22.93% |
| 2020 | $1.07B | 76.59% |
| 2019 | $607.57M | 26.26% |
| 2018 | $481.19M | 10.37% |
| 2017 | $435.96M | 78.42% |
| 2016 | $244.35M | 214.60% |
| 2015 | $77.67M | -19.17% |
| 2014 | $96.09M | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $12.62B | 282.80% |
US
|
|
| $2.23B | -32.44% |
US
|
|
| $15.74B | 377.41% |
AU
|
|
| $10.11B | 206.59% |
BE
|
|
| $6.02B | 82.58% |
NL
|
